Rationale and protocol design for the TORG1835/NEXT-SHIP study: a phase II study of carboplatin, etoposide and nintedanib for unresectable limited/extensive disease small cell lung cancer with idiopathic pulmonary fibrosis

  • Satoshi Ikeda, Takashi Ogura, Terufumi Kato, Hirotsugu Kenmotsu, Tae Iwasawa, Toshihiro Misumi, Takeharu Yamanaka, Hiroaki Okamoto
  • Therapeutic Advances in Medical Oncology, January 2020, SAGE Publications
  • DOI: 10.1177/1758835920923431

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

http://dx.doi.org/10.1177/1758835920923431

The following have contributed to this page: Satoshi Ikeda